New Therapeutic Targets and Drugs for Schizophrenia Beyond Dopamine D2 Receptor Antagonists
DOI: https://doi.org/10.2147/ndt.s455279
IF: 2.989
2024-03-20
Neuropsychiatric Disease and Treatment
Abstract:Aineng Peng, 1 Jianbo Chai, 2 Haiyuan Wu, 1 Bing Bai, 3 Huihui Yang, 1 Weizhi He, 1 Yonghou Zhao 2 1 Heilongjiang University of Chinese Medicine, Harbin, 150040, People's Republic of China; 2 Heilongjiang Mental Hospital, Harbin, 150036, People's Republic of China; 3 Tongde Hospital of Zhejiang Province, Hangzhou, 311100, People's Republic of China Correspondence: Yonghou Zhao, Heilongjiang Mental Hospital, 153 Hengdao Street, Harbin, Heilongjiang, 150036, People's Republic of China, Tel +86 13904638645, Email Schizophrenia is a disease with a complex pathological mechanism that is influenced by multiple genes. The study of its pathogenesis is dominated by the dopamine hypothesis, as well as other hypotheses such as the 5-hydroxytryptamine hypothesis, glutamate hypothesis, immune-inflammatory hypothesis, gene expression abnormality hypothesis, and neurodevelopmental abnormality hypothesis. The first generation of antipsychotics was developed based on dopaminergic receptor antagonism, which blocks dopamine D2 receptors in the brain to exert antipsychotic effects. The second generation of antipsychotics acts by dual blockade of 5-hydroxytryptamine and dopamine receptors. From the third generation of antipsychotics onwards, the therapeutic targets for antipsychotic schizophrenia expanded beyond D2 receptor blockade to explore D2 receptor partial agonism and the antipsychotic effects of new targets such as D3, 5-HT1A, 5-HT7, and mGlu2/3 receptors. The main advantages of the second and third generation antipsychotics over first-generation antipsychotics are the reduction of side effects and the improvement of negative symptoms, and even though third-generation antipsychotics do not directly block D2 receptors, the modulation of the dopamine transmitter system is still an important part of their antipsychotic process. According to recent research, several receptors, including 5-hydroxytryptamine, glutamate, γ-aminobutyric acid, acetylcholine receptors and norepinephrine, play a role in the development of schizophrenia. Therefore, the focus of developing new antipsychotic drugs has shifted towards agonism or inhibition of these receptors. Specifically, the development of NMDARs stimulants, GABA receptor agonists, mGlu receptor modulators, cholinergic receptor modulators, 5-HT2C receptor agonists and alpha-2 receptor modulators has become the main direction. Animal experiments have confirmed the antipsychotic effects of these drugs, but their pharmacokinetics and clinical applicability still require further exploration. Research on alternative targets for antipsychotic drugs, beyond the dopamine D2 receptor, has expanded the potential treatment options for schizophrenia and gives an important way to address the challenge of refractory schizophrenia. This article aims to provide a comprehensive overview of the research on therapeutic targets and medications for schizophrenia, offering valuable insights for both treatment and further research in this field. Keywords: schizophrenia, target, neurotransmitter, antipsychotic drugs Schizophrenia is a common clinical psychiatric disorder that most often begins in youth or early adulthood, with multiple impairments in perception, thinking, emotion, cognition, behavior, and social functioning. Schizophrenia affects about 1% of the global population and has a low cure rate, often accompanied by emotional apathy and impaired social functioning, which has a significant impact on the quality of life of both patients and their families. 1 According to a survey, schizophrenia caused an economic loss of $343.2 billion in the United States in 2019, which places a significant burden on the economy. 2 There are metabolic syndrome complications in schizophrenia, and the side effects of antipsychotic drugs further aggravate metabolic disorders and increase cardiovascular risk in patients, and these seriously affect the quality of life and survival age of patients; therefore, there is an urgent need to find more effective and safer medications for the treatment of schizophrenia. A variety of neurotransmitters are involved in regulating the mental activity of the body, and abnormal functioning of neurotransmitter receptors is closely related to schizophrenia. Dopamine, glutamate, 5-hydroxytryptamine, acetylcholine, and norepinephrine are the most common neurotransmitters affecting schizophrenia. Previous research on antipsychotic drugs has primarily focused on dopamine receptor antagonists. However, in recent years, there has been a gradual increase in research on drugs that act on glutamate receptors, 5-hydroxytryptamine receptors, acetylcholine receptors and norepinephrine receptors to treat psychiatric disorders. Dopamine (DA) dysregulation is a significant c -Abstract Truncated-
psychiatry,clinical neurology